The Journal of Nutrition Nutrition and Disease
Plasma Selenium Concentrations Are Sufficient and Associated with Protease Inhibitor Use in Treated HIV-Infected Adults1–3 Corrilynn O Hileman,4,5 Sahera Dirajlal-Fargo,5,6 Suet Kam Lam,6 Jessica Kumar,6 Craig Lacher,7 Gerald F Combs Jr.,7 and Grace A McComsey5,6* 4 Department of Medicine, Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, OH; 5Case Western Reserve University School of Medicine, Cleveland, OH; 6Department of Pediatrics, Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and ChildrenÕs Hospital, Cleveland, OH; and 7Grand Forks Human Nutrition Research Center, USDA Agricultural Research Service, Grand Forks, ND
Abstract Background: Selenium is an essential constituent of selenoproteins, which play a substantial role in antioxidant defense and inflammatory cascades. Selenium deficiency is associated with disease states characterized by inflammation, including cardiovascular disease (CVD). Although HIV infection has been associated with low selenium, the role of selenium status in HIV-related CVD is unclear. Objectives: We sought to assess associations between plasma selenium and markers of inflammation, immune activation, and subclinical vascular disease in HIV-infected adults on contemporary antiretroviral therapy (ART) and to determine if statin therapy modifies selenium status. Methods: In the Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN trial, HIV-infected adults on stable ART were randomly assigned 1:1 to rosuvastatin or placebo. Plasma selenium concentrations were determined at entry, week 24, and week 48. Spearman correlation and linear regression analyses were used to assess relations between baseline selenium, HIV-related factors and markers of inflammation, immune activation, and subclinical vascular disease. Changes in selenium over 24 and 48 wk were compared between groups. Results: One hundred forty-seven HIV-infected adults were included. All participants were on ART. Median current CD4+ count was 613, and 76% had HIV-1 RNA #48 copies/mL (range:
Plasma Selenium Concentrations Are Sufficient and Associated with Protease Inhibitor Use in Treated HIV-Infected Adults1–3 Corrilynn O Hileman,4,5 Sahera Dirajlal-Fargo,5,6 Suet Kam Lam,6 Jessica Kumar,6 Craig Lacher,7 Gerald F Combs Jr.,7 and Grace A McComsey5,6* 4 Department of Medicine, Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, OH; 5Case Western Reserve University School of Medicine, Cleveland, OH; 6Department of Pediatrics, Division of Pediatric Infectious Diseases and Rheumatology, Rainbow Babies and ChildrenÕs Hospital, Cleveland, OH; and 7Grand Forks Human Nutrition Research Center, USDA Agricultural Research Service, Grand Forks, ND
Abstract Background: Selenium is an essential constituent of selenoproteins, which play a substantial role in antioxidant defense and inflammatory cascades. Selenium deficiency is associated with disease states characterized by inflammation, including cardiovascular disease (CVD). Although HIV infection has been associated with low selenium, the role of selenium status in HIV-related CVD is unclear. Objectives: We sought to assess associations between plasma selenium and markers of inflammation, immune activation, and subclinical vascular disease in HIV-infected adults on contemporary antiretroviral therapy (ART) and to determine if statin therapy modifies selenium status. Methods: In the Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN trial, HIV-infected adults on stable ART were randomly assigned 1:1 to rosuvastatin or placebo. Plasma selenium concentrations were determined at entry, week 24, and week 48. Spearman correlation and linear regression analyses were used to assess relations between baseline selenium, HIV-related factors and markers of inflammation, immune activation, and subclinical vascular disease. Changes in selenium over 24 and 48 wk were compared between groups. Results: One hundred forty-seven HIV-infected adults were included. All participants were on ART. Median current CD4+ count was 613, and 76% had HIV-1 RNA #48 copies/mL (range:
